Mary R Rooney1, Olive Tang2, James S Pankow3, Elizabeth Selvin2. 1. Department of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, USA. mroone12@jhu.edu. 2. Department of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, USA. 3. Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, USA.
Abstract
AIMS/HYPOTHESIS: There is controversy regarding the performance of HbA1c in old age. We evaluated the prognostic value of HbA1c and other glycaemic markers (fructosamine, glycated albumin, fasting glucose) with mortality risk in older adults (66-90 years). METHODS: This was a prospective analysis of 5636 participants (31% with diagnosed diabetes, mean age 76, 58% female, 21% black) in the Atherosclerosis Risk in Communities (ARIC) study, baseline 2011-2013. We used Cox regression to examine associations of glycaemic markers (modelled in categories) with mortality risk, stratified by diagnosed diabetes status. RESULTS: During a median of 6 years of follow-up, 983 deaths occurred. Among older adults with diabetes, 30% had low HbA1c (<42 mmol/mol [<6.0%]) and 10% had high HbA1c (≥64 mmol/mol [≥8.0%]); low (HR 1.32 [95% CI 1.04, 1.68]) and high (HR 1.86 [95% CI 1.32, 2.62]) HbA1c were associated with mortality risk vs HbA1c 42-52 mmol/mol (6.0-6.9%) after demographic adjustment. Low fructosamine and glycated albumin were not associated with mortality risk. Both low and high fasting glucose were associated with mortality risk. After further adjustment for lifestyle and clinical risk factors, high HbA1c (HR 1.81 [95% CI 1.28, 2.56]), fructosamine (HR 1.96 [95% CI 1.43-2.69]), glycated albumin (HR 1.81 [95% CI 1.33-2.47]) and fasting glucose (HR 1.81 [95% CI 1.24, 2.66]) were associated with mortality risk. Low HbA1c and fasting glucose were no longer significantly associated with mortality risk. Among participants without diabetes, associations of glycaemic markers with mortality risk were less robust. CONCLUSIONS/ INTERPRETATION: Elevated HbA1c, fructosamine, glycated albumin and fasting glucose were associated with risk of mortality in older adults with diabetes. Low HbA1c and fasting glucose may be markers of poor prognosis but are possibly confounded by health status. Our findings support the clinical use of HbA1c in older adults with diabetes. Graphical abstract.
AIMS/HYPOTHESIS: There is controversy regarding the performance of HbA1c in old age. We evaluated the prognostic value of HbA1c and other glycaemic markers (fructosamine, glycated albumin, fasting glucose) with mortality risk in older adults (66-90 years). METHODS: This was a prospective analysis of 5636 participants (31% with diagnosed diabetes, mean age 76, 58% female, 21% black) in the Atherosclerosis Risk in Communities (ARIC) study, baseline 2011-2013. We used Cox regression to examine associations of glycaemic markers (modelled in categories) with mortality risk, stratified by diagnosed diabetes status. RESULTS: During a median of 6 years of follow-up, 983 deaths occurred. Among older adults with diabetes, 30% had low HbA1c (<42 mmol/mol [<6.0%]) and 10% had high HbA1c (≥64 mmol/mol [≥8.0%]); low (HR 1.32 [95% CI 1.04, 1.68]) and high (HR 1.86 [95% CI 1.32, 2.62]) HbA1c were associated with mortality risk vs HbA1c 42-52 mmol/mol (6.0-6.9%) after demographic adjustment. Low fructosamine and glycated albumin were not associated with mortality risk. Both low and high fasting glucose were associated with mortality risk. After further adjustment for lifestyle and clinical risk factors, high HbA1c (HR 1.81 [95% CI 1.28, 2.56]), fructosamine (HR 1.96 [95% CI 1.43-2.69]), glycated albumin (HR 1.81 [95% CI 1.33-2.47]) and fasting glucose (HR 1.81 [95% CI 1.24, 2.66]) were associated with mortality risk. Low HbA1c and fasting glucose were no longer significantly associated with mortality risk. Among participants without diabetes, associations of glycaemic markers with mortality risk were less robust. CONCLUSIONS/ INTERPRETATION: Elevated HbA1c, fructosamine, glycated albumin and fasting glucose were associated with risk of mortality in older adults with diabetes. Low HbA1c and fasting glucose may be markers of poor prognosis but are possibly confounded by health status. Our findings support the clinical use of HbA1c in older adults with diabetes. Graphical abstract.
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: Naomi Brewer; Craig S Wright; Noémie Travier; Chris W Cunningham; John Hornell; Neil Pearce; Mona Jeffreys Journal: Diabetes Care Date: 2008-02-25 Impact factor: 19.112
Authors: E B Levitan; S Liu; M J Stampfer; N R Cook; K M Rexrode; P M Ridker; J E Buring; J E Manson Journal: Diabetologia Date: 2007-11-28 Impact factor: 10.122
Authors: Lydie N Pani; Leslie Korenda; James B Meigs; Cynthia Driver; Shadi Chamany; Caroline S Fox; Lisa Sullivan; Ralph B D'Agostino; David M Nathan Journal: Diabetes Care Date: 2008-07-15 Impact factor: 17.152
Authors: Morgana Mongraw-Chaffin; Alain G Bertoni; Sherita Hill Golden; Nestoras Mathioudakis; Dorothy D Sears; Moyses Szklo; Cheryl A M Anderson Journal: J Endocr Soc Date: 2019-03-01
Authors: Mary R Rooney; Natalie Daya; Olive Tang; John William McEvoy; Josef Coresh; Robert H Christenson; Elizabeth Selvin Journal: Clin Chem Date: 2022-03-04 Impact factor: 8.327
Authors: Amelia S Wallace; Mary R Rooney; Tammy M Brady; Justin B Echouffo-Tcheugui; Robert Christenson; Morgan E Grams; Elizabeth Selvin Journal: Pediatr Diabetes Date: 2021-12-26 Impact factor: 4.866
Authors: Caitlin W Hicks; Dan Wang; Kunihiro Matsushita; John W McEvoy; Robert Christenson; Elizabeth Selvin Journal: Diabetes Res Clin Pract Date: 2022-01-20 Impact factor: 5.602